Clinical Trials on Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck in Poland

Total 277 results

Exicure, Inc.

Terminated

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Advanced or Metastatic Melanoma | Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

United States
BioAtla, Inc.

Recruiting

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma of the Head and Neck

United States
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
Rakuten Medical, Inc.

Active, not recruiting

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma

United States
AbbVie
Idera Pharmaceuticals, Inc.

Completed

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Advanced Solid Tumors Cancer

United States, France, Germany, Israel, Netherlands, Spain
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE147)

Squamous Cell Carcinoma of the Head and Neck

United States
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

United States, Canada, France, Spain, Belgium, Czechia, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Australia, Germany, Georgia, Israel
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; IO Biotech

Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)

Head and Neck Squamous Cell Carcinoma

United States
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute

Withdrawn

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma

United States
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
Providence Health & Services
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab for Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Maria Sklodowska-Curie National Research Institute...
Centre of Postgraduate Medical Education

Completed

The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck | Esophageal Squamous Cell Carcinoma

Poland
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Leiden University Medical Center
HollandPTC

Terminated

Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck (ERM-PT-HNSCC)

Squamous Cell Carcinoma of the Head and Neck

Netherlands
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute; Galecto Biotech... and other collaborators

Recruiting

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma

United States
Erasmus Medical Center

Recruiting

Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer (GuidedbyLight)

Squamous Cell Carcinoma of the Head and Neck | Oral Cancer | Squamous Cell Carcinoma of the Oral Cavity

Netherlands
Providence Health & Services
MedImmune LLC; Providence Cancer Center, Earle A. Chiles Research Institute

Active, not recruiting

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Melanoma | Head and Neck Cancer | Carcinoma, Squamous Cell | Head and Neck Squamous Cell Carcinoma | Cell Cancer, Squamous

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, Italy, Canada, Korea, Republic of, United Kingdom, Germany, Vietnam, Japan, France, India, Taiwan, Thailand, Malaysia, Turkey, Brazil, Belgium, Poland, Austria, Hungary
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Head and Neck Cancer

France, Russian Federation, Spain, United Kingdom, Germany, Hungary, Poland, Ukraine, Austria, Netherlands, Slovakia, Sweden, Switzerland, Belgium, Italy, Portugal, Czech Republic
MedImmune LLC

Completed

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Iovance Biotherapeutics, Inc.

Completed

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
AstraZeneca

Completed

SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (SUPREME-HN)

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Korea, Republic of, Spain, Greece, Germany, Japan
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)

Head and Neck Cancer

Italy, United States, Israel, Japan, Australia, Austria, Brazil, France, Germany, Greece, Ireland, Korea, Republic of, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom
Erasmus Medical Center

Not yet recruiting

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial (STELLAR)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Hypopharynx

Netherlands
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
Replimune Inc.
Bristol-Myers Squibb

Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, United Kingdom, Czechia, France, Germany, Greece, Poland
Providence Health & Services
Galectin Therapeutics Inc.

Completed

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Melanoma | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute

Active, not recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Korea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute

Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Genome & Company
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Urothelial Carcinoma

United States
Sesen Bio, Inc.

Terminated

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Squamous Cell Carcinoma of the Head and Neck | Neoplasms, Squamous Cell | Mouth Neoplasms

United States, Canada
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
PCI Biotech AS

Terminated

A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.

Recurrent Head and Neck Cancer | Carcinoma, Squamous Cell of Head and Neck

Germany, United Kingdom, France, Lithuania, Netherlands, Poland
Joris B.W. Elbers
Erasmus Medical Center; HollandPTC

Recruiting

HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC (HYDRA)

Head and Neck Squamous Cell Carcinoma | Radiotherapy | Proton Therapy | Hypofractionation | Immune System Suppression

Netherlands

Clinical Trials on Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations